A5100735321- Adipose Tissue and Metabolism
- Regulation of Appetite and Obesity
- Nutrition and Health in Aging
- Muscle Physiology and Disorders
- Metabolism, Diabetes, and Cancer
- Body Composition Measurement Techniques
- Adipokines, Inflammation, and Metabolic Diseases
- Diet and metabolism studies
Geriatric Research Education and Clinical Center
2023-2024
University of Puget Sound
2023-2024
University of Washington
2023-2024
Seattle University
2023
Our study was to characterize sarcopenia in C57BL/6J mice using a clinically relevant definition investigate the underlying molecular mechanisms. Aged male (23-32 months old) and female (27-28 were classified as non-, probable-, or sarcopenic based on assessments of grip strength, muscle mass, treadmill running time, 2 SDs below mean their young counterparts cutoff points. A 9%-22% prevalence identified 23-26 month-old mice, with more severe age-related declines function than mass. Females...
Abstract Background Ghrelin is a potential therapy for cachexia due to its orexigenic properties and anabolic effects on muscle fat. However, clinical use limited by the short half‐life of active (acylated) ghrelin (~11 min in humans). EXT418 novel long‐acting, constitutively analog created covalently linking it vitamin D derivative. Here, we evaluated mechanisms action Lewis lung carcinoma (LLC)‐induced mice. Methods Male C57BL/6J mice (5‐ 7‐month‐old) were implanted with 1 × 10 6...
Abstract The hormone ghrelin serves a protective role in cancer-related anorexia-cachexia syndrome (CACS) – condition which plasma levels of rise, its administration lessens CACS severity, and experimentally-reduced signaling by receptor (GHSR) worsens fat loss anorexia accelerates death. Yet, actions for the related liver-expressed antimicrobial peptide-2 (LEAP2), is an endogenous GHSR antagonist, are unexplored CACS. Here, we found that LEAP2 LEAP2/ghrelin ratio were lower Lewis Lung...
Abstract Cancer cachexia (muscle wasting leading to functional impairment) is experienced by most individuals with cancer and increases age. There are no approved treatments in the U.S./E.U. because Phase III trials have failed achieve endpoints. Identification of metabolites/metabolic pathways related poor performance may reveal therapeutic targets but metabolomics analyses only examined weight loss and/or muscle mass. We characterized metabolomic perturbations plasma abdominal wall...